Indeed, in a study using the ALK5 inhibitor SM16 in rats subjected to aortic banding, the treatment efficiently reduced fibrosis, but resulted in left ventricular dilatation and increased mortality due to the rupture of the aortic banding site [71]. The gene discussed is TGFBR1; the disease is Left ventricular dilatation.